Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
- The Rosen Law Firm PAROSEN, NATIONAL TRIAL LAWYERS, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Hagens Berman Sobol Shapiro LLPCAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitNational investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A...
- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line PatientsImmuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of the federal securities laws.
- Vimy Pharmaceuticals Corp.Vimy Pharmaceuticals Announces Brokered Private Placement of Subscription ReceiptsVimy Pharmaceuticals Inc. ("Vimy Pharma" or the "Company") and Harmony Acquisitions Corp. (TSXV: MONY.P) ("Harmony") are pleased to jointly announce that, further to their press release dated August 6, 2026 announcing the entering into of a non-binding letter of intent to complete a business combination transaction which will constitute a reverse take-over of Harmony (the "Transaction"), Vimy Pharma has launched a "best efforts" brokered...
- First Tracks Biotherapeutics IncFirst Tracks Biotherapeutics Announces Participation in September Investor ConferencesFirst Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also...
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerThis release contains multimedia assets available for download here
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to a Securities Law InvestigationKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
- Robbins LLPRobbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period").The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with...
- JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in DermatomyositisPriovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.